Related Experiment Video
Updated: Dec 3, 2025
09:58
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
Published on: April 13, 2010
23.0K
Short-acting bronchodilators purchase as a marker for asthma control
Dekel Shlomi1,2, Bernice Oberman3, Irit Katz4
1Adelson School of Medicine, Ariel University, Ariel, Israel.
Summary
Three or more short-acting bronchodilator purchases annually may indicate poor asthma control. Alerts for low controller medication use can help physicians and patients manage asthma effectively.
Area of Science:
- Pulmonology
- Pharmacoeconomics
- Health Informatics
Background:
- Administrative data aids in quantifying medication use to identify at-risk asthma patients.
- Previous research utilized short-acting beta-agonists (SABA) inhalers as a marker for asthma control.
- This study builds upon prior work by further analyzing patient data related to asthma control markers.
Purpose of the Study:
- To analyze patient data to assess asthma control using GINA guidelines, physician assessment, and patient self-estimation.
- To compare inhaled and systemic steroid use in relation to bronchodilator purchases.
- To identify thresholds for short-acting bronchodilator purchases that may indicate poor asthma control.
Main Methods:
- Analysis of patient data from a SABA inhalers study, including GINA guideline classification, physician assessment, and patient estimation of asthma control.
- Identification of all short-acting bronchodilator purchases (SABA and anticholinergic inhalers/solutions) in the year preceding questionnaire administration.
- Comparison of inhaled and systemic steroid use based on asthma control levels.
Main Results:
- Out of 241 asthma patients, 83 completed questionnaires.
- Based on GINA criteria, 26 patients had symptom-controlled asthma, 46 were partially controlled, and 11 were uncontrolled.
- Patients with partially controlled and uncontrolled asthma showed significantly higher mean annual short-acting bronchodilator purchases (10 and 8.9, respectively) compared to controlled patients (2).
- The majority of asthma patients purchase less than 50% of their prescribed controller medications.
Conclusions:
- An annual purchase of 3 or more short-acting bronchodilators should prompt physicians to evaluate asthma control.
- Purchase alerts for low controller medication consumption should notify both physicians and patients.
- Administrative data on medication purchases can serve as a valuable tool for monitoring and managing asthma control.
Related Concept Videos
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
1.5K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.5K
01:30Asthma-IV: Diagnostic and Management
2.9K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.9K
01:17Drugs Used in Lower Respiratory Disorders: Overview
867
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
867
01:23Inhaled Medications
572
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
572
01:26COPD: Management Using Bronchodilators and Corticosteroids
579
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
579
01:19Antiasthma Drugs: Leukotriene Modifiers
1.6K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.6K